Author

C. K. Jons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:rat· 1

Frequent Co-Authors

J. Yan· 4 shared C. L. Maikawa· 3 shared E. A. Appel· 3 shared A. I. d'Aquino· 2 shared A. K. Grosskopf· 2 shared B. S. Ou· 2 shared E. Appel· 2 shared J. Baillet· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

J. Yan

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Drive Distinct Immune Signatures and Potent Vaccine Responses

B. S. Ou, J. Baillet, M. V. Filsinger Interrante, J. Z. Adamska, X. Zhou, O. Saouaf, J. Yan, J. Klich, C. K. Jons, E. Meany, A. S. Valdez, L. Carter, B. Pulendran, N. P. King, E. Appel

This paper develops a modular saponin-based nanoparticle adjuvant platform incorporating TLR agonists, showing improved vaccine potency and breadth against COVID-19 and HIV in mice.

bioRxiv · Jul 16, 2023 · PreprintBioengineering

Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes

A. I. d'Aquino, C. L. Maikawa, L. T. Nguyen, K. Lu, I. A. Hall, C. K. Jons, C. I. Kasse, J. Yan, A. N. Prossnitz, E. Chang, S. W. Baker, L. Hovgaard, D. B. Steensgaard, H. B. Andersen, L. Simonsen, E. A. Appel

This paper develops a hydrogel-based GLP-1 receptor agonist delivery system that provides sustained therapy for up to 42 days in rats, improving diabetes management compared to daily injections.

bioRxiv · Jan 28, 2023 · PreprintBioengineering

Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot

C. M. Kasse, A. C. Yu, A. E. Powell, G. A. Roth, C. S. Liong, C. K. Jons, A. Buahin, C. L. Maikawa, S. Youssef, J. E. Glanville, E. A. Appel

This paper develops a supramolecular hydrogel depot for subcutaneous delivery of SARS-CoV-2 bnAbs, showing prolonged release and improved pharmacokinetics compared to standard administration.

bioRxiv · May 24, 2022Bioengineering

Yield Stress and Creep Control Depot Formation and Persistence of Injectable Hydrogels Following Subcutaneous Administration

C. K. Jons, A. K. Grosskopf, J. Baillet, J. Yan, J. H. Klich, E. A. Appel

This study investigates how hydrogel rheological properties affect depot formation and persistence after subcutaneous injection in mice.

bioRxiv · Apr 20, 2022Bioengineering

Delivery of CAR-T Cells in a Transient Injectable Stimulatory Hydrogel Niche Improves Treatment of Solid Tumors

A. K. Grosskopf, L. Labanieh, D. D. Klysz, G. Roth, P. Xu, O. Adebowale, E. C. G. C. Gale, C. K. Jons, J. H. Klich, J. Yan, C. L. Maikawa, S. Correa, B. S. Ou, A. I. d'Aquino, J. R. Cochran, , E. Appel

This paper develops an injectable hydrogel to co-deliver CAR-T cells and cytokines, enhancing solid tumor treatment in mice by creating a transient inflammatory niche.

bioRxiv · Dec 20, 2021Bioengineering